NT5C2 novel splicing variant expands the phenotypic spectrum of Spastic Paraplegia (SPG45): case report of a new member of thin corpus callosum SPG-Subgroup
- Mahmoud F. Elsaid1,
- Khalid Ibrahim†1,
- Nader Chalhoub†2, 3,
- Ahmed Elsotouhy4,
- Noora El Mudehki5 and
- Alice Abdel Aleem2, 3Email author
© The Author(s). 2017
Received: 30 August 2016
Accepted: 7 March 2017
Published: 21 March 2017
Hereditary Spastic Paraplegia (HSP) is a genetically heterogeneous group of neurodegenerative diseases. Thin Corpus Callosum (TCC) associated HSP is a distinguished subgroup of complex forms. Purines and pyrimidine, the basic DNA and RNA components, are regulating the cell metabolism, having roles in signal transduction, energy preservation and cellular repair. Genetic defects in nucleotide metabolism related genes have been only recently implicated in brain and neurodegenerative diseases’ pathogenesis.
We present a consanguineous Qatari family with two brothers, 9 and 3 years, who displayed a characteristic phenotype of early onset and markedly-severe spasticity with tiptoe walking, delayed dysarthric speech, persistent truncal hypotonia, and multiple variable-sized areas of brownish skin discoloration appearing at different places on the body. A clinical diagnosis suggestive of complex hereditary spastic paraplegia (HSP) was set after the family had the second affected child. Whole genome sequencing identified a novel homozygous NT5C2 splice site mutation (NM_012229.4/NM_001134373.2: c.1159 + 1G > T) that recessively segregated in family members. Brain MRI revealed dysgenic and thin corpus callosum (TCC) with peri-trigonal white matter cystic changes in both affected boys, whereas a well-developed corpus callosum with normal white matter was shown in their apparently normal brother, who found to be a carrier for the mutant variant. This mutation led to skipping of exon 14 with removal of 58 amino acid residues at the C-terminal half. The aberrantly spliced NT5C2 showed substantial reduction in expression level in the in-vitro study, indicating marked instability of the mutant NT5C2 protein.
The present report expands the phenotypic spectrum of SPG45 and confirms NT5C2-SPG45 as a member of the rare TCC SPG-subtypes. Homozygous alteration in NT5C2 seems essential to produce central white matter developmental defects. The study highlights the importance of cytosolic II 5’-nucleotidase (NT5C2) in maintaining the normal balance of purines’ pool in the brain, which seems to play a pivotal role in the normal development of central white matter structures.
KeywordsHereditary spastic paraplegia SPG-Thin corpus callosum subgroup Nucleotide metabolism NT5C2 SPG45 SPG45-brain MRI
Hereditary spastic paraplegia (HSP) is a large, genetically heterogeneous group of neurodegenerative diseases characterized by retrograde degeneration of axons of motor neurons of the corticospinal tract . A rare subgroup of the HSP recessive-forms was described with a brain-imaging marker of thin corpus callosum (TCC), for which a set of few genes has been identified so far . Genetic defects in nucleotide metabolism related genes have been only recently implicated in HSP pathogenesis . Nucleotidases are a group of hydrolases classified according to their subcellular localization and sites of cleavage. The 5’ nucleotidases catalyze the hydrolysis of 5’ ribo- and deoxyribo-nucleotide monophosphate into the corresponding nucleoside. The 5’ nucleotidase cytosolic II (NT5C2) enzyme has a critical role in maintaining the balance of nucleotides, nucleosides and free nucleobases of purine’s pools in the brain and spinal cord . NT5C2 catalyzes the hydrolysis of Adenosine Monophosphate and Inosine Monophosphate releasing Adenosine. Adenosine has been recently recognized to have a key role in promoting myelin formation in the central nervous system (CNS) . Adenosine inhibits proliferation of oligodendrocytes progenitor cells (OPC), whereas it stimulates their differentiation into mature oligodendrocytes and modulates the communication of the neuron and glial cells with the axons [6–8]. This study describes a consanguineous Qatari family with a provisional clinical diagnosis of complex-HSP, in which the HSP-genes panel testing failed to detect the underlying gene defect. By using whole genome sequencing (WGS) and ingenuity variant data analysis (IVA) we were able to identify a novel homozygous splice site mutation in NT5C2 that recessively segregates in the family. The NT5C2 gene involvement in HSP families from Middle East has been reported only once before, however; this is the first report in Qatari patients and demonstrates new clinical findings and interesting observations.
Patient II.3 is the youngest (3 years old) of three brothers of consanguineous parents (Fig. 2a). Developmental delay was the first sign that drew the parents’ attention. He remained unable to crawl or sit until the age of 10 months and started tiptoe-walking at the age of 2 years. Progressive spasticity of the lower limbs; limited ankles’ dorsiflexion and hips abduction, with ankle clonus and brisk (+4) reflexes, sitting with bending curved back due to truncal hypotonia, delayed speech and mild mental impairments were his main presentations. His gait was unsteady with knees flexion and lumber lordosis to help to achieve balance.
Patient II.1 is the oldest brother (9 years old). Although he is similarly affected, he was originally misdiagnosed for cerebral palsy because of prematurity and early lower limb spasticity. Postnatally, he was admitted to the NICU because of respiratory distress; however, no mechanical ventilation was required. By the age of 4 months, his lower limbs were markedly spastic with scissoring. As a 2-year-old, his speech and motor developmental delay were notable. He could not sit unsupported for long periods, but could take a few steps while holding onto objects with evident lower limbs spasticity and marked truncal hypotonia. He started to speak when he was 3 years old. On examination, he was alert and cooperative despite delay in active speech. His gait, performed with difficulty for few steps, demonstrated tiptoe walking with limited knee and hip extension and trunk flexion.
At 2 and 3 years old, he was admitted to an inpatient pediatric rehabilitation and training program for 4 months each, which aimed to support motor and speech development. The response was good, as gross motor functions, including sitting, crawling and kneeling, standing, and walking for a short distance without support or orthopedic aid, became possible. He showed a more secure and significantly improved gait, and was able to pick up objects from the ground and walk up to 600 meters without supportive aids. His Gross Motor Function Measure (GMFM) chart, at the age of 3 years showed continued improvements with the percentage of sitting 100%, standing 74% and walking 56%. However, as a 7-year-old, he underwent tenotomies for his spastic hips and ankles.
Follow up at 9 years showed him to have an unsupported gait with primary forefoot contact, knee in flexion and lumber lordosis. Features of truncal hypotonia, markedly limited ankle dorsiflexion and ankle clonus were notable.
Brain Magnetic Resonance Imaging (MRI) of the two affected boys showed dysgenic/TCC and white matter cystic changes (Fig. 1.2). Images of the unaffected brother (heterozygous for the mutation) showed well-developed Corpus Callosum.
Phenotypic Characteristics in SPG45 patients with NT5C2 mutations
Families described in Ref.3
Age at onset
15 &18 months, infancy, or Unknown
Range between 2 and 33 years old with a mean of 30 years
Presentation at disease onset
Marked lower limbs spasticity and developmental delay
Developmental delay and marked lower limbs spasticity
+ (speech started at age 3 years)
+ (speech started at age 2 and half years)
Lower limbs Spasticity
Can walk unsupported with abnormal gait
Can walk unsupported with tip toe walking and abnormal gait
Some can walk unsupported, others walk with support
+ (Unsteady gait while walking associated with lumber lordosis, knees flexion, limited foot movements, limited knees and hips extension.
+ (Tip toe walking, in-toing, knee flexion (milder than older brother), lordosis, unsteadiness because of movements limitation.
+ (some cases showed associated knees flexion contracture)
+ (attending special school)
+ (except in one family reported with normal cognition)
Latent convergent Squint improved following correction glasses, optic disk normal
Hyper-metrope, no squint, normal optic disk
Squint, glaucoma, or primary optic atrophy, each sign was reported once in a patient
TCC, CC dysgenesis, white matter cystic changes and hyperintensities
Similar findings in addition to frontal cerebral atrophy
TCC & white matter changes in 4 families with available images
Variable size patches of brownish discoloration begin to appear at 6 years old
- (he is yet at the age of 3 years)
Equinus foot in one family
+ [he developed the control just lately]
Nocturnal enuresis in only one case
The NT5C2-related phenotype has previously been clinically assigned to SPG45 (MIM: 613162). This report describes a homozygous novel NT5C2 splice-site mutation in two Qatari siblings with AR-HSP. This mutation resulted in markedly altered stability of the enzyme-protein. NT5C2 involvement in recessive HSP was reported once before in a large HSP-cohort study . The splice mutation identified in this study is located at the C-terminal half of the protein and led to in-frame skipping of exon 14. The significantly deficient expression of mutant NT5C2 shown in in-vitro overexpression experiment highlights the substantial impact of exon 14 skipping on protein stability and/or its proper folding; hence a loss of function mutant is assumed.
The six reported NT5C2 mutations, so far, (3 and this report) (Additional file 3: Table S1) seems to lead to the same path of loss of function. Even so the impact of previously described NT5C2 mutations on the encoded protein was not tested, however they were predicted to be deleterious and impair the protein function .
Phenotypic features of delayed and dysarthric speech, persistent truncal hypotonia, variable-sized patches of skin brownish discoloration and the early-onset, markedly severe spasticity were first described in our patients, expanding the phenotypic spectrum of SPG45.
The skin patches started to appear at 6 years of age; hence it was detectable only in the older patient. There was no clinical reason found for those patches. Altered nucleotide metabolism might be an explanation; follow up with the younger patients might provide a clue.
The capacity to maintain the walking ability despite the marked spasticity (this report) and even in the longest reported disease duration [3, 10] is of a good prognostic value to SPG45 families with NT5C2 mutations.
Studying the brain imaging of the two patients versus the unaffected carrier brother was quite interesting. Brain MRI findings strongly support the observation that homozygous mutation involving the two copies of NT5C2 is essential to producing the developmental defects in cerebral white matter with dysgenic/TCC. By contrast, the heterozygous status of the mutation in the unaffected brother was associated with normal development of cerebral white matter (Fig. 1.2). Brain images in our cases backed by reports of previously described families with available MRI  distinguish SPG45 (NT5C2) as an additional member of SPG-TCC subgroup.
Taken together, the mature oligodendrocytes are the main myelin forming cells in the brain and Adenosine is both a modulator of OPC development and a potent neuron-glial-axonal transmitter, it is likely that the normal adenosine and purines’ pool concentrations in the brain has an influence on the normal developmental process of myelin formation in the CNS. Further experiments are necessary to verify this assumption.
We recognized a striking similarity in the key clinical features involving TCC, markedly severe spasticity and long disease duration with maintained ability of unsupported walking in families with NT5C2 (SPG45) or DDHD2 (SPG54) mutations [11, 12]. Mutated phospholipase DDHD2 was suggested to affect both the dynamics and/or morphology of Golgi and ER in a retrograde or anterograde transport mechanism [13, 14] as well as the complex lipid metabolism [15, 16]. Whether there might be a common mechanism potentially linking the NT5C2 loss of function, disturbed purines’ signaling to the transport along the corticospinal tract and/or membrane trafficking, remains a hypothesis awaiting further studies.
The present report confirms the critical role of cytosolic 5’nucleotidase and nucleotide metabolism in the normal development of central white matter structures and warrants further experiments to explore a potential role of 5’ nucleotidase in transport and/or maintenance along the corticospinal tract. The NT5C2 c.1159 + 1G > T splicing mutation presents a phenotype of markedly severe and early onset spasticity, persistent truncal hypotonia, delayed-dysarthric speech and skin patches of darkened discoloration. These characteristic features expanding the phenotypic spectrum of SPG45. The present family emphasizes SPG45 with NT5C2 mutations as a member of the TCC-SPG subgroup. Of the notable observation is the good prognosis of the recessive complex SPG45 in terms of mild cognitive impairment with some learning difficulties and the maintained unsupported walking ability, however with abnormal gait.
See Additional file 4: Supplementary methods.
Hereditary spastic paraplegia
Ingenuity variant analysis
Nucleotidase 5’ cytosolic II
Oligodendrocytes progenitor cells
Reverse transcriptase polymerase reaction
This Corpus Callosum
whole genome sequencing
The authors are thankful to family members for their participation in the study. We thank Ms. Amira Assad, the study research coordinator and Dr. Adam Larson for his critical reading of the manuscript.
This study was supported by Qatar Foundation-National Priority Research Fund; Grant NPRP5-448-3-118.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its supplementary information files]. The WGS Variants calling dataset that support the findings of this study are available from Weill Cornell Medical College (WCMCQ) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of WCMCQ.
ME, KhI and NEl: evaluated the patients clinically and edited the manuscript. NCh: performed the molecular experiments, wrote the molecular results, prepared the figures and edited the manuscript. AEl: select the MRI images and wrote the images’ legend. AA: evaluate the patients clinically, collect the genetic information, drafted the manuscript and edited to final version. The authors approve the submitted version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written consent has been obtained from the parents/legal guardians for publication.
Ethics approval and consent to participate
The Institutional Review Board of Weill Cornell Medical College-Qatar and Hamad Medical Corporation-Qatar approved this study. Written informed consent was obtained from all participants prior to clinical data and blood samples collection. A copy of the ICF is available for review as requested.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hensiek A, Kirker S, Reid E. Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing. J Neurol. 2015;262:1601–12.View ArticlePubMedGoogle Scholar
- Pensato V, Castellotti B, Gellera C, et al. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain. 2014;137:1907–20.View ArticlePubMedGoogle Scholar
- Novarino G, Fenstermaker A, Zaki M, et al. Exome Sequencing Links Corticospinal Motor Neuron Disease to Common Neurodegenerative Disorders. Science. 2014;343:506–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Camici M, Micheli V, Ipata PL, Tozzi MG. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int. 2010;56:367–78.View ArticlePubMedGoogle Scholar
- Matute C, Cavaliere F. Neuroglial interactions mediated by purinergic signalling in the pathophysiology of CNS disorders. Semin Cell Dev Biol. 2011;22:252–9.View ArticlePubMedGoogle Scholar
- Inoue K. Microglial Activation by Purines and Pyrimidines. GLIA. 2002;40:156–63.View ArticlePubMedGoogle Scholar
- Fields D, Burnstock G. Purinergic signalling in neuron–glia interactions. Nat Rev Neurosci. 2006;7:423–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Coppi E, Cellai L, Maraula G, et al. Role of Adenosine in oligodendrocyte precursor maturation. Front Cell Neurosci. 2015;9:155.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodriguez-Flores JL, Fakhro K, Agosto-Perez F, et al. Indigenous Arabs are descendants of the earliest split from ancient Eurasian populations (PMID: 26728717). With a link to bam files on SRA database. Genome Res. 2016;26:151–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Dursun U, Koroglu C, Orhan EK, Ugur SA, Tolun A. Autosomal recessive spastic paraplegia (SPG45) with mental retardation maps to 10q24.3–q25.1. Neurogenetics. 2009;10:325–31.View ArticlePubMedGoogle Scholar
- Gonzalez M, Nampoothiri S, Kornblum C, et al. Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54). Eur J Hum Genet. 2013;21:1214–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, et al. Mutations in DDHD2, Encoding an Intracellular Phospholipase A, Cause a Recessive Form of Complex Hereditary Spastic Paraplegia. Am J Hum Genet. 2012;91:1073–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Sato S, Inoue H, Kogure T, Tagaya M, Tani K. Golgi-localized KIAA0725p regulates membrane trafficking from the Golgi apparatus to the plasma membrane in mammalian cells. FEBS Lett. 2010;584:4389–95.View ArticlePubMedGoogle Scholar
- Morikawa RK, Aoki J, Kano F, Murata M, Yamamoto A, Tsujimoto M, Arai H. Intracellular phospholipase A1gamma (iPLA1-gamma) is a novel factor involved in coat protein complex I- and Rab6-independent retrograde transport between the endoplasmic reticulum and the golgi complex. J Biol Chem. 2009;284:26620–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Kooijman EE, Chupin V, de Kruijff B, Burger KN. Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Traffic. 2003;4:162–74.View ArticlePubMedGoogle Scholar
- Wang X, Devaiah SP, Zhang W, Welti R. Signaling functions of phosphatidic acid. Prog Lipid Res. 2006;45:250–78.View ArticlePubMedGoogle Scholar